Ghent University Academic Bibliography

Advanced

Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer

Ana Maria Luiza Olteanu UGent, Fréderic Duprez UGent, Wilfried De Neve UGent, Dieter Berwouts UGent, Tom Vercauteren, Wouter Bauters, Philippe Deron UGent, Wouter Huvenne UGent, Katrien Bonte, Ingeborg Goethals UGent, et al. (2018) ACTA ONCOLOGICA. 57(2). p.262-268
abstract
Background: To identify predictive factors for the development of late grade 4 mucosal ulcers in adaptive dose-escalated treatments for head-and-neck cancer. Material and methods: Patient data of four dose-escalated three-phase adaptive dose-painting by numbers (DPBN) clinical trials were analyzed in this study. Correlations between the development of late grade 4 ulcers and factors related with the treatment, disease characteristics and the patient were investigated. Dosimetrical thresholds were searched among the highest doses received by 1.75cm(3) (D-1.75cc) of the primary gross tumor volume (GTV(T)) and the corresponding normalized isoeffective dose (NID2(1.75cc), with a reference dose of 2Gy/fraction and alpha/beta of 3Gy). Results: From 39 studied patients, nine developed late grade 4 mucosal ulcers. The continuation to either smoke or drink alcohol after therapy was the factor that showed a strong (eight out of nine patients) association with the occurrence of grade 4 ulcers. Six of the patients who continued to smoke or/and drink had D-1.75cc and NID2(1.75cc) above 84Gy and 95.5Gy, respectively. Seven of the patients with grade 4 had the dose levels above these thresholds, but even if the D-1.75cc threshold was significant in the prediction of late grade 4 ulcers, it could not be considered as the only contributing factor. Conclusions: The search for patterns provided strong reasons to apply a dosimetrical threshold for the peak-dose volume of 1.75cm(3) as a preventive measure for late grade 4 mucosal ulcers. Also, patients that continue to smoke or drink alcohol after therapy have increased risk to develop late mucosal ulcers.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
LOCALLY ADVANCED HEAD, SEVERE LATE TOXICITY, QUALITY-OF-LIFE, PHASE-I, TRIAL, RTOG ANALYSIS, RADIOTHERAPY, NUMBERS, BRACHYTHERAPY, SMOKING, IMRT
journal title
ACTA ONCOLOGICA
Acta Oncol.
volume
57
issue
2
pages
262 - 268
Web of Science type
Article
Web of Science id
000423473200014
ISSN
0284-186X
1651-226X
DOI
10.1080/0284186X.2017.1364867
language
English
UGent publication?
yes
classification
U
id
8551149
handle
http://hdl.handle.net/1854/LU-8551149
date created
2018-02-20 13:25:54
date last changed
2018-06-14 12:56:47
@article{8551149,
  abstract     = {Background: To identify predictive factors for the development of late grade 4 mucosal ulcers in adaptive dose-escalated treatments for head-and-neck cancer. 
Material and methods: Patient data of four dose-escalated three-phase adaptive dose-painting by numbers (DPBN) clinical trials were analyzed in this study. Correlations between the development of late grade 4 ulcers and factors related with the treatment, disease characteristics and the patient were investigated. Dosimetrical thresholds were searched among the highest doses received by 1.75cm(3) (D-1.75cc) of the primary gross tumor volume (GTV(T)) and the corresponding normalized isoeffective dose (NID2(1.75cc), with a reference dose of 2Gy/fraction and alpha/beta of 3Gy). 
Results: From 39 studied patients, nine developed late grade 4 mucosal ulcers. The continuation to either smoke or drink alcohol after therapy was the factor that showed a strong (eight out of nine patients) association with the occurrence of grade 4 ulcers. Six of the patients who continued to smoke or/and drink had D-1.75cc and NID2(1.75cc) above 84Gy and 95.5Gy, respectively. Seven of the patients with grade 4 had the dose levels above these thresholds, but even if the D-1.75cc threshold was significant in the prediction of late grade 4 ulcers, it could not be considered as the only contributing factor. 
Conclusions: The search for patterns provided strong reasons to apply a dosimetrical threshold for the peak-dose volume of 1.75cm(3) as a preventive measure for late grade 4 mucosal ulcers. Also, patients that continue to smoke or drink alcohol after therapy have increased risk to develop late mucosal ulcers.},
  author       = {Olteanu, Ana Maria Luiza and Duprez, Fr{\'e}deric and De Neve, Wilfried and Berwouts, Dieter and Vercauteren, Tom and Bauters, Wouter and Deron, Philippe and Huvenne, Wouter and Bonte, Katrien and Goethals, Ingeborg and Schatteman, Julie and De Gersem, Werner},
  issn         = {0284-186X},
  journal      = {ACTA ONCOLOGICA},
  keyword      = {LOCALLY ADVANCED HEAD,SEVERE LATE TOXICITY,QUALITY-OF-LIFE,PHASE-I,TRIAL,RTOG ANALYSIS,RADIOTHERAPY,NUMBERS,BRACHYTHERAPY,SMOKING,IMRT},
  language     = {eng},
  number       = {2},
  pages        = {262--268},
  title        = {Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer},
  url          = {http://dx.doi.org/10.1080/0284186X.2017.1364867},
  volume       = {57},
  year         = {2018},
}

Chicago
Olteanu, Ana Maria Luiza, Fréderic Duprez, Wilfried De Neve, Dieter Berwouts, Tom Vercauteren, Wouter Bauters, Philippe Deron, et al. 2018. “Late Mucosal Ulcers in Dose-escalated Adaptive Dose-painting Treatments for Head-and-neck Cancer.” Acta Oncologica 57 (2): 262–268.
APA
Olteanu, A. M. L., Duprez, F., De Neve, W., Berwouts, D., Vercauteren, T., Bauters, W., Deron, P., et al. (2018). Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer. ACTA ONCOLOGICA, 57(2), 262–268.
Vancouver
1.
Olteanu AML, Duprez F, De Neve W, Berwouts D, Vercauteren T, Bauters W, et al. Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer. ACTA ONCOLOGICA. 2018;57(2):262–8.
MLA
Olteanu, Ana Maria Luiza, Fréderic Duprez, Wilfried De Neve, et al. “Late Mucosal Ulcers in Dose-escalated Adaptive Dose-painting Treatments for Head-and-neck Cancer.” ACTA ONCOLOGICA 57.2 (2018): 262–268. Print.